An update from RemeGen Co. Ltd. Class H ( (HK:9995) ) is now available.
RemeGen Co., Ltd. has announced a board meeting scheduled for April 28, 2025, to consider and approve the unaudited first quarterly results for the period ending March 31, 2025. This meeting is significant as it will provide insights into the company’s financial performance and could impact its market positioning and stakeholder confidence.
More about RemeGen Co. Ltd. Class H
RemeGen Co., Ltd. is a joint stock company incorporated in the People’s Republic of China, operating within the pharmaceutical industry. The company focuses on the development and commercialization of innovative biologics and drugs, catering to various medical needs.
YTD Price Performance: 98.61%
Average Trading Volume: 5,312,020
Technical Sentiment Signal: Sell
Current Market Cap: HK$22.69B
For an in-depth examination of 9995 stock, go to TipRanks’ Stock Analysis page.